Q1 2021 Dealmaker Roundup
Life sciences gets a COVID booster shot
In this edition of the Dealmaker Roundup, RSM’s Life Sciences Senior Analyst, Adam Lohr, and Jamie Hendershot, Transaction Advisory Director, along with Sean Cunningham, Managing Director at GTCR, share insights about dramatic changes in the industry over the pandemic year.
This Privcap hosted discussion addresses:
- What's driving the surging IPO market for biotech companies,
- How clinical trials have continued apace during COVID,
- Considerations for investing in tool-making companies versus drug developers, and
- The need for private equity partners to bring more to the table than just money.